Vor Bio (VOR)pharma announced that it has commenced an underwritten public offering of $100M of shares of its common stock. All of the shares are being offered by Vor Bio. J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the proposed offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio achieves primary endpoint in Stage A of Phase 3 study of telitacicept
- Vor Biopharma Appoints New Chief Medical Officer
- Vor Bio appoints Sokolove as Chief Medical Officer
- Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study
- Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split